First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Elanco Animal Health Incorporated

    ELAN · 2 developments mapped · last assessed 2026-09-22

    Market Ontology has mapped 2 macro, policy, and market developments to Elanco Animal Health Incorporated since 2026-09-07. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for ELAN yet, so no modelled value is shown. The ELAN valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run ELAN on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for ELAN. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Open question

      Virbac generates €768M H1 revenue as currency headwinds trim headline growth to 4.0%

      Peer performance and industry trends, particularly regarding global animal health market demand and currency impacts.

      · Moves industry growth rate, foreign exchange rate assumptions

    What changed, by assumption

    Industry growth rate
    • 2026-09-07Virbac generates €768M H1 revenue as currency headwinds trim headline growth to 4.0%
    Regulatory approval timelines
    • 2026-09-22Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-22Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYAwatch1-5y0.10
    2026-09-07Virbac generates €768M H1 revenue as currency headwinds trim headline growth to 4.0%watch1-3m0.30